HCW Biologics Inc.
HCW Biologics Inc. (HCWB): 52 pipeline candidates · 1 upcoming catalyst · ~3 mo cash runway · 23 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
2.6 months
D/E 3.74
Lead: Phase 3
52 candidates
1 upcoming, next in ~561d
3 buys · 0 sells (180d)
A transparent, data-derived signal for HCW Biologics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.9M
Cash
$1.2M
Quarterly Burn
$1.6M
Runway
2.6 mo
Revenue
$6.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (52 candidates)
| Drug | Phase |
|---|---|
| adsorbed acellular pertussis diphtheria-tetanus-pertussis | Phase 3 |
| atg-101 | Phase 1 |
| db-3q | Phase 2 |
| diphtheria | Phase 3 |
| dr30206 | Phase 1 |
| dr30303 | Phase 1 |
| dtcp-hib-mcv4 | Phase 1 |
| exoflo | Phase 3 |
| haemophilus influenzae type b | Phase 1 |
| hcw11-018b | Preclinical |
Showing 10 of 52 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$45K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 35,886 | $13K |
| citadel advisors llc | 26,083 | $9K |
| vanguard capital management llc | 24,046 | $9K |
| jane street group, llc | 14,134 | $5K |
| citigroup inc | 10,528 | $4K |
| golden state wealth management, llc | 10,000 | $4K |
| vanguard fiduciary trust co | 1,903 | $685 |
| wells fargo & company/mn | 1,000 | $360 |
| hrt financial lp | 266,393 | $95 |
| osaic holdings, inc. | 26 | $9 |
Showing top 10 of 12 institutional holders of HCW Biologics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in HCW Biologics Inc.'s pipeline?
HCW Biologics Inc. (HCWB) has 52 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HCW Biologics Inc.'s lead drug candidate?
HCW Biologics Inc.'s most advanced tracked candidate is adsorbed acellular pertussis diphtheria-tetanus-pertussis (Phase 3) for Diphtheria, Tetanus and Acellular Pertussis.
What is HCW Biologics Inc.'s next catalyst?
HCW Biologics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Mode" — expected December 31, 2027.
What is HCW Biologics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HCW Biologics Inc. has approximately 2.6 months of cash runway.
What is HCW Biologics Inc.'s market capitalization?
HCW Biologics Inc.'s market capitalization is approximately $7.9M.
Get the full picture on HCW Biologics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.